Guillain–Barré syndrome, or GBS, is one of the most urgent neurological disorders in which the body’s immune system attacks the peripheral nerves. Weakness can spread rapidly from the legs upward, sometimes affecting the muscles needed for breathing, swallowing and maintaining heart-rate stability. Because early treatment can reduce complications and shorten recovery, physicians often search for laboratory clues that support the diagnosis while monitoring a patient’s clinical progression. A new systematic review and meta-analysis published in the Journal of Neurology examines one of the most widely used clues in this setting: increased protein in the cerebrospinal fluid, or CSF, without a corresponding rise in the number of white blood cells.
This laboratory pattern is known as albuminocytologic dissociation. It reflects a mismatch between two CSF measurements. Protein levels rise, largely because inflammation or disruption around the spinal nerve roots allows plasma proteins such as albumin to enter the fluid, while the white-cell count remains normal or only minimally elevated. The finding is associated with GBS, but it is neither exclusive to the syndrome nor guaranteed to appear during the first days of illness. The new analysis focuses on precisely this uncertainty, asking how often CSF protein elevation and albuminocytologic dissociation are detected at different stages of GBS and how the diagnostic threshold used by laboratories changes the apparent frequency of the finding.
The timing of lumbar puncture is central to the interpretation. GBS often evolves over days, and the biological processes that alter the blood–nerve barrier may not immediately produce a measurable increase in CSF protein. A sample taken very early can therefore appear normal even when the patient is developing a classic immune-mediated neuropathy. As the disease progresses, protein accumulation becomes more likely, making a later sample more informative for some patients. The study’s time-dependent approach places this familiar clinical observation on a quantitative footing, emphasizing that a negative early CSF result should not automatically be treated as evidence against GBS.
The researchers also address a second source of variation: the threshold used to define “elevated” CSF protein. Laboratories may apply different reference limits depending on the testing method, patient age and local population. A strict cutoff can identify more pronounced abnormalities but may miss modest increases, particularly in the early phase of disease. A lower or age-adjusted threshold may detect more cases, although it can also reduce specificity if other neurological or systemic conditions produce mild protein elevations. By comparing threshold-dependent definitions, the meta-analysis highlights that the reported diagnostic yield of CSF testing is partly shaped by laboratory policy rather than by the disease alone.
That distinction matters because GBS remains a clinical diagnosis supported, rather than replaced, by ancillary tests. Physicians evaluate the pattern and speed of weakness, loss of reflexes, sensory symptoms, cranial-nerve involvement and evidence of autonomic dysfunction. Nerve-conduction studies can reveal demyelination or axonal injury, while CSF analysis provides information about the environment surrounding the nerve roots. In practice, clinicians must combine these findings with the patient’s timeline and exclude conditions that can mimic GBS, including spinal-cord compression, toxic neuropathies, metabolic disorders, inflammatory diseases and certain infections. The meta-analysis reinforces the role of CSF protein as one component of a broader diagnostic framework.
The findings are also relevant to patients whose illness follows an infection. GBS is frequently described as post-infectious because immune activation may arise after gastrointestinal or respiratory infections, although the neurological syndrome itself is not usually caused by an actively replicating virus in the nerves. Molecular mimicry, in which immune responses directed against microbial molecules cross-react with components of peripheral nerves, is one proposed mechanism for several GBS subtypes. Campylobacter jejuni, cytomegalovirus, Epstein–Barr virus and other infectious exposures have been associated with the syndrome, and sporadic cases have also been investigated after viral illnesses, including SARS-CoV-2 infection. These associations do not eliminate the need for direct neurological assessment, and they do not make CSF protein a stand-alone test for an infectious cause.
A major value of a systematic review and meta-analysis is that it can bring together evidence from many cohorts, where individual studies may differ in patient selection, sampling time, laboratory technique and diagnostic criteria. Those differences can make the literature appear contradictory. One study may report a relatively low frequency of albuminocytologic dissociation because most lumbar punctures were performed soon after weakness began, while another may report a higher frequency because samples were collected later or because a different protein cutoff was used. By examining these variables together, the new work helps explain why published estimates have varied and why the same patient might receive different interpretations in different clinical settings.
The analysis has practical implications for emergency and inpatient care. When GBS is strongly suspected, treatment decisions should not necessarily wait for a later CSF abnormality, particularly if weakness is progressing or respiratory and autonomic functions are threatened. Intravenous immunoglobulin and plasma exchange are established therapies for appropriate patients, and early recognition is essential because deterioration can be swift. At the same time, an abnormal CSF protein result obtained after several days may strengthen diagnostic confidence, especially when the cell count remains low. Conversely, an early normal result should be understood as a time-sensitive snapshot rather than a definitive exclusion of disease. Repeat testing may be considered when the clinical picture continues to evolve, although the decision depends on the patient’s condition and the need to avoid unnecessary procedures.
The study ultimately presents CSF analysis as a dynamic biomarker rather than a simple yes-or-no test. Protein elevation in GBS reflects changing pathology around the nerve roots, while albuminocytologic dissociation depends on when the fluid is collected and which reference limit is applied. That message may help clinicians communicate uncertainty more accurately, reduce false reassurance from early negative samples and interpret published diagnostic percentages with greater caution. It also points toward a broader goal for future research: standardized sampling intervals, age-sensitive protein thresholds and more consistent reporting of disease subtypes could make CSF findings easier to compare across countries and hospitals. For a syndrome in which hours can matter, understanding when a test becomes informative may be nearly as important as knowing what the test measures.
Subject of Research: Time- and threshold-dependent cerebrospinal fluid protein elevation and albuminocytologic dissociation in Guillain–Barré syndrome
Article Title: Time- and threshold-dependent cerebrospinal fluid protein elevation and albuminocytologic dissociation in Guillain–Barré syndrome: a systematic review and meta-analysis
Article References: Journal of Neurology, 2026. DOI: 10.1007/s00415-026-14024-4
Image Credits: AI Generated
DOI: 10.1007/s00415-026-14024-4
Keywords: Guillain–Barré syndrome, cerebrospinal fluid, albuminocytologic dissociation, CSF protein, lumbar puncture, neurological diagnosis, peripheral neuropathy, systematic review, meta-analysis, diagnostic timing
